Treating the neurons and me — my mental states — in a synergistic way proved to speed up and enhance healing. It does for ...

NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9, 2024Expects full year 2025 pro forma ...

NFL journey and the fears he had around his struggles and symptoms that he knew whole-heartedly was CTE,” his daughter said ...

A man has been charged after a crash between a van and a horse in Cornwall, police have said. An eight-year-old girl was ...

The company's recent acquisition of Greenbrook TMS, a network of mental health treatment clinics, has been cited as a transformative move for Neuronetics. Post-acquisition adjustments reveal a pro ...

We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

Spinraza remains a big product for Biogen but has seen its sales go into reverse as competition in SMA treatment has emerged ...